Team leader
Yasuo Yoshioka
Objectives of the team
The DDS/adjuvant research team aims to design/develop DDS/adjuvants to achieve maximal performance of mRNA vaccines.
Description of research and development by the team
This team strives toward the development of lipid nanoparticles (LNPs) for modifying mRNA vaccines, which is useful in preventing adverse vaccine reactions as well as improving vaccine efficacy. The team also develops improved LNPs that can induce persistent antibody production and elicit on-target immune responses through our distinctive adjuvants, cell-specific peptides, and other proprietary technologies.
Tasks of the team
- 1Development of novel LNPs for mRNA vaccines
- 2Development of LNPs for combined use with adjuvants
- 3Development of cell-targeting LNPs
- 4Development of human resource capable of pursuing interdisciplinary research on DDS and vaccinology
